Specialized drinks containing L-arginine, omega-3 fatty acids, and nucleotides given before and after bladder cancer surgery failed to reduce 30-day complications compared to standard nutrition in a 203-person randomized trial . Survival trends favored immunonutrition but were not statistically significant.
Radical cystectomy (surgical removal of the bladder) for bladder cancer is one of the higher-risk surgical procedures, with complication rates typically exceeding 60 percent. Researchers at 13 US cancer centers tested whether "immunonutrition"—oral drinks fortified with specific compounds thought to support immune function—could improve outcomes. The theory was sound: L-arginine, omega-3 fatty acids, and dietary nucleotides have shown some immune-supporting properties in laboratory and smaller studies. If these ingredients could prime the immune system before surgery, the logic went, patients might suffer fewer infections and other post-operative complications.
The SWOG S1600 trial enrolled 203 patients with bladder cancer scheduled for cystectomy between 2019 and 2023. Participants drank either the immunonutrition formula or standard nutritional support three times daily for five days before surgery and five days after. The drinks were identical except for the added immune-supporting ingredients, and neither patients nor researchers knew who received which version. With 178 patients completing 30-day follow-up assessments, the results were clear: immunonutrition did not prevent complications. Any complication within 30 days occurred in 62 percent of the immunonutrition group versus 58 percent of the standard nutrition group. For high-grade complications (infections, bleeding, reoperation), the rates were 11 percent versus 12.5 percent, respectively. These differences favor neither approach and fall well within the range of chance variation.
The trial did record one notable difference: patients in the immunonutrition group reported more adverse events, primarily nausea (34 percent vs. 21 percent). This suggests the specialized formula may have been less tolerable, though the vast majority of participants adhered to the protocol. Two-year survival outcomes showed a trend favoring immunonutrition (87 percent overall survival vs. 78 percent, and 77 percent disease-free survival vs. 68 percent), but these differences were not statistically significant and could easily reflect chance given the modest sample size and play of probability over 24 months.
The negative primary outcome here is informative. This was a well-designed, adequately powered study conducted across multiple institutions with strong protocol adherence. The researchers measured dietary compliance using a plasma biomarker (the ratio of arachidonic acid to eicosapentaenoic acid), confirming 94.5 percent of participants actually consumed what they were assigned. This rules out poor adherence as an explanation. The study design, execution, and transparent reporting of both favorable and unfavorable findings are hallmarks of trustworthy evidence.
If you're facing bladder surgery, this study suggests that commercially available immunonutrition drinks are unlikely to reduce your risk of post-operative complications compared to standard nutritional support. Patients undergoing major surgery remain vulnerable to infection and other complications regardless of these supplements. The takeaway is not that nutrition doesn't matter before surgery—it does—but rather that these specific fortified formulations don't provide an additional benefit over baseline nutrition. Focus instead on conventional pre-operative optimization: adequate protein intake, management of comorbidities, and adherence to your surgical team's specific pre-operative instructions.
The nausea signal is also worth noting. If you do choose to use immunonutrition formulas perioperatively, expect potential gastrointestinal effects, particularly from the added omega-3 and nucleotide content. Standard protein-based approaches may be equally effective and better tolerated.
For the broader oncology community, this result tempers enthusiasm for specialized perioperative nutrition in high-risk surgery. It doesn't eliminate the role of nutritional support, but it clarifies that supplementation beyond standard nutrition is not a magic preventive tool. Further research into which patient subgroups (if any) might benefit from immunonutrition, or what specific nutrient combinations might prove effective, remains warranted as the authors note.
| Attribute | Detail |
|---|---|
| Study type | Randomized controlled trial, double-blind, phase 3 |
| Sample size | 203 enrolled; 178 completed 30-day follow-up |
| Age (median) | 68.8 years (range 32-95) |
| Sex | 79.8% male |
| Sites | 13 US academic and community cancer centers |
| Enrollment | March 2019 to October 2023 |
| Primary outcome | Any 30-day complication (Clavien-Dindo grade ≥1) |
| Immunonutrition components | L-arginine, omega-3 fatty acids, dietary nucleotides |
| Duration | 5 days preoperative + 5 days postoperative |
| Adherence | 94.5% (measured via plasma biomarker) |
| Primary result | 62.2% complications (immunonutrition) vs. 58.0% (standard); OR 1.18 (95% CI 0.64-2.18) |
| High-grade complications | 11.1% vs. 12.5%; OR 0.86 (95% CI 0.34-2.17) |
| 2-year overall survival |
Hussain SA, et al. Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. JAMA Netw Open. 2025. PubMed 42475098
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.
| Adverse events | 34.1% vs. 20.5% (nausea most common) |
| Journal | JAMA Network Open |
| PubMed ID | 42475098 |